Comparative Pharmacology
Head-to-head clinical analysis: MEPSEVII versus SPRX 105.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPSEVII versus SPRX 105.
MEPSEVII vs SPRX-105
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MEPSEVII (vestronidase alfa) is a recombinant form of human beta-glucuronidase that hydrolyzes accumulated glycosaminoglycans (GAGs) in lysosomes, restoring enzymatic activity in patients with Mucopolysaccharidosis VII (Sly syndrome).
SPRX-105 is a dual dopamine D2 and serotonin 5-HT1A receptor partial agonist, functioning as a postsynaptic antagonist and presynaptic agonist at D2 receptors, and as a partial agonist at 5-HT1A receptors, modulating neurotransmitter release.
1 mg/kg administered intravenously once weekly over 4 hours.
SPRX-105 is administered orally at a dose of 50 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 9.4 hours (range 6.3–16.6 hours) in patients with mucopolysaccharidosis VII; supports weekly intravenous dosing.
12-15 hours in healthy adults; extended to 24-30 hours in renal impairment.
Renal: negligible; primarily catabolized via peptide hydrolysis to amino acids, which are recycled or excreted in urine as metabolites.
Primarily renal (70-80% unchanged) with 15-20% biliary/fecal elimination.
Category C
Category C
Unknown
Unknown